Nanobodies, nucleic acid molecules and their applications in sweeteners
By using camel-derived natural phage display technology to screen nanobodies that bind to sweet taste receptors, the health risks of existing sweeteners and the stability and production costs of natural sweet proteins have been addressed. This has enabled the stable expression of sweetness from nanobodies, providing possibilities for the development of novel sweeteners.
Patent Information
- Application Number
- CN202510620818.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-14
- Publication Date
- 2026-11-17
AI Technical Summary
Existing sweeteners such as aspartame and sucralose pose health risks. Natural sweet proteins suffer from low thermal stability, high production costs, and low yields. There is also a lack of nanobodies that specifically bind to sweet taste receptors.
Nanobodies that specifically bind to the extracellular region of sweet taste receptors were screened using camel-derived natural phage display technology. The nanobodies were then prepared and purified using a nucleic acid molecular encoding and vector expression system to achieve high-affinity binding to the sweet taste receptors.
Stable expression of nanobodies was obtained, which can induce a sweet taste response and have a sweet taste effect. This provides a new approach to the research and development of sweeteners and solves the health risks of existing sweeteners and the stability and production cost problems of natural sweet proteins.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to nanobodies (Nb) that can specifically bind to sweet taste receptors, nucleic acid molecules, and their application in sweeteners. Background Technology
[0002] Sugar is a direct energy source for cells. Against this backdrop, artificial sweeteners have emerged. As a class of low-calorie molecules that provide sweetness, artificial sweeteners are favored by consumers, driving the proliferation of "zero-sugar" beverages and sweetener-substituted snacks. While artificial sweeteners do reduce daily energy intake, their potential health risks are increasingly attracting the attention of scientists. In July 2023, the common artificial sweetener aspartame was classified as a Group 2B carcinogen, sparking widespread concern.
[0003] Since the 20th century, excessive sugar intake has led to concerns about obesity and diabetes, prompting a surge in demand for natural sugar alternatives and giving rise to both artificial and natural sweeteners. For example, steviol glycosides and mogrosides, due to their natural extraction and low-calorie properties, have become representative natural sweeteners for healthy diets in the 21st century. Artificial sweeteners can be traced back to 1879 with the introduction of saccharin, the first synthetic sweetener, which was 300 times sweeter than sucrose. However, its application was limited due to controversies surrounding its bitter aftertaste and potential carcinogenicity. Aspartame, developed in 1965, is 200 times sweeter than sucrose and is widely used in beverages and pharmaceuticals. However, recent studies have shown that mice with aspartame intake below 15% exhibit anxiety behaviors and spatial learning and memory deficits. These adverse effects are heritable, suggesting a potential risk to human health from aspartame. A 2025 research paper published in *Cell Metabolism* further revealed that long-term aspartame intake may promote atherosclerosis by activating the CX3CL1 signaling pathway, highlighting the necessity of addressing aspartame's safety concerns. At the end of the 20th century, sucralose and acesulfame potassium became mainstream sweeteners due to their heat resistance and high stability. However, a March 2023 study in *Nature*, titled "Dietary sucralose is a negative regulator of T cell responses," showed that high doses of sucralose intake limit T cell function in mice. In recent years, numerous studies have confirmed that artificial sweeteners are not inert in the human body; they significantly affect the gut microbiota, thereby influencing blood sugar levels. Total intake of artificial sweeteners is associated with an increased risk of cardiovascular and cerebrovascular diseases; further research suggests that the artificial sweetener erythritol may be linked to heart disease. These findings all indicate that the intake of artificial sweeteners poses potential health risks. Therefore, compared to the numerous health risks associated with artificial sweeteners, natural sweeteners and sweetened proteins are preferred due to their safety profile.
[0004] Sweet proteins are natural food products extracted from plants. They are characterized by high sweetness, low calories, no increase in blood sugar, and the ability to be broken down into various amino acids needed by the human body after digestion. Currently, eight types of sweet proteins are known: Thaumatin, Brazzein, Monellin, Pentadin, Mabinlin, Miraculin, Neoculin, and Curculin. In the 1970s, Thaumatin and Monellin were isolated from West African plants. Thaumatin is about 2,000 to 3,000 times sweeter than sucrose, while Monellin is 100,000 times sweeter. However, Monellin's application is limited due to its poor thermal stability and high extraction cost. In the 21st century, genetic engineering and fermentation technology have driven the large-scale production of sweet proteins. Breakthroughs in synthetic biology technology in 2024 significantly increased the yield of Brazzein, but its production cost is still higher than that of traditional sweeteners. Sweet protein proteins have entered the high-end food and pharmaceutical fields thanks to their "natural" label, such as in sugar substitutes for diabetics. However, the acidity and instability of some sweet proteins in high-temperature environments, as well as the lag in regulatory approvals, have kept their application in a bottleneck period. For example, the European Food Safety Authority has not yet completed the safety assessment of areca nut sweet protein. As of 2025, only the sweet protein sematrandine has been approved for use as a food additive. Although sematrandine is already widely used in the food industry, its dosage needs to be strictly controlled to avoid allergies.
[0005] Humans experience five basic tastes: sour, sweet, bitter, salty, and umami. Sweet, bitter, and umami tastes are mediated by related receptors. Taste buds are the human taste receptors; there are approximately 5,000 taste buds on the human tongue, distributed on the upper surface, palate, and epiglottis. Taste receptor cells are concentrated on these taste buds. When activated by taste substances, these cells transmit information to specific taste perception areas in the brain. The two subunits of the sweet taste receptor are expressed in different papillae. T1R2 is mainly expressed in the taste buds of the circumferential and foliate papillae, with a small amount expressed in the taste buds of the fungiform papillae. Approximately 30% of the cells in the taste buds of these three types of papillae express T1R3. Sequence and structural analysis indicate that the sweet taste receptor belongs to the C-class GPCR family, characterized by a large extracellular domain. This domain consists of an N-terminal Venus flytrap module (VFTM) and a cysteine-rich domain (CRD). The CRD connects the VFTM to a seven-helical transmembrane domain (TMD) and an intracellular domain (ID). Studies activating receptors in xenograft cells in vitro have revealed that T1R3 can only interact with most sweeteners in the presence of T1R2, and that either T1R2 or T1R3 alone is merely a low-affinity receptor for sugar. The extracellular domain of sweet taste receptors is a core structural domain in the sweet taste recognition mechanism, and its function is closely related to the specific binding of sweet taste molecules and signal transduction.
[0006] Nanobodies (Nb) are the smallest known antibody fragments capable of binding to antigens, with a molecular weight of only 15 kDa. They possess characteristics such as high specificity, strong affinity, low immunogenicity, high stability, and strong penetrability. However, whether and how to obtain nanobodies for novel sweeteners remains a subject of in-depth research. Summary of the Invention
[0007] The purpose of this invention is to provide nanobodies that can bind to sweet taste receptors, providing a new approach for the development of novel sweeteners. This aims to address the problems of harmful effects of artificial sweeteners on the human body, as well as the low thermal stability, high production cost, and low yield of natural sweet proteins, and is expected to serve as a completely new type of sweetener.
[0008] The technical solutions for achieving the above objectives include the following.
[0009] A first aspect of the present invention is to provide a nanobody for a sweetener, comprising a framework region and a complementarity-determining region, said nanobody being selected from at least one of the following:
[0010] a. The frame regions are shown in SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13 and SEQ ID NO:15, and the complementary determination regions CDR1 to CDR3 are shown in SEQ ID NO:10, SEQ ID NO:12 and SEQ ID NO:14;
[0011] b. The frame regions are shown in SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21 and SEQ ID NO:23, and the complementary determination regions CDR1 to CDR3 are shown in SEQ ID NO:18, SEQ ID NO:20 and SEQ ID NO:22;
[0012] c. The frame regions are shown in SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29 and SEQ ID NO:31, and the complementarity determination regions CDR1 to CDR3 are shown in SEQ ID NO:26, SEQ ID NO:28 and SEQ ID NO:30;
[0013] d. The frame regions are shown in SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 and SEQ ID NO:39, and the complementarity determination regions CDR1 to CDR3 are shown in SEQ ID NO:34, SEQ ID NO:36 and SEQ ID NO:38.
[0014] In some embodiments, the amino acid sequence of the nanobody is as shown in any of SEQ ID NO:1-SEQ ID NO:4, or the nanobody is selected from the amino acid sequences shown in SEQ ID NO:1-SEQ ID NO:4 by substitution, deletion or addition of one or more amino acids without changing its sweetener activity.
[0015] In some preferred embodiments, the substitution, deletion, or addition of one or more amino acids is the substitution, deletion, or addition of at least one, at least two, or at least three amino acids.
[0016] In some preferred embodiments, the amino acid sequences of the nanobody are shown in SEQ ID NO:2 and SEQ ID NO:3.
[0017] A second objective of the present invention is to provide a nucleic acid molecule encoding any of the above-mentioned nanobodies for sweeteners, or a carrier in which said nucleic acid molecule is inserted and can express said nanobodies.
[0018] The nucleic acid molecules can be DNA molecules and RNA molecules that encode nanobodies.
[0019] In some embodiments, nucleic acid molecules encoding nanobodies are shown as SEQ ID NO:5-SEQ ID NO:8.
[0020] In some embodiments, the vector is a plasmid, a bacteriophage, a granule, or a bacteriophage or viral vector.
[0021] More preferably, the vector is the prokaryotic vector pET25b plasmid.
[0022] A host cell that expresses any of the aforementioned nanobodies.
[0023] Preferably, the host cell is a prokaryotic cell or a eukaryotic cell;
[0024] More preferably, the host cell is a bacterial cell or a yeast cell. In some embodiments, the host cell expressing the nanobody is Escherichia coli BL21(DE3).
[0025] A third objective of this invention is to provide a method for preparing nanobodies for sweeteners, comprising the following steps:
[0026] The host cells are cultured to obtain the nanobody from the culture.
[0027] In some embodiments, the method for preparing the nanobody for sweetener includes cloning a nucleic acid molecule encoding any of the above-mentioned nanobody into a prokaryotic expression vector, culturing it, extracting a polypeptide from the culture, purifying it, and obtaining the nanobody.
[0028] Alternatively, a method for preparing nanobodies for sweeteners, comprising the following steps:
[0029] The phage display technology was used to screen for sweet taste receptor extracellular antigen proteins.
[0030] In some of these embodiments, the sweet taste receptor extracellular antigen protein is as shown in SEQ ID NO:41 and / or SEQ ID NO:42.
[0031] A fourth objective of this invention is to provide the use of the nanobody, or the aforementioned carrier, or the aforementioned host cell in the preparation of sweeteners.
[0032] The fifth objective of this invention is to provide a sweetener whose main active ingredient includes the above-mentioned nanobody or the above-mentioned carrier.
[0033] This invention uses the extracellular region of the sweet taste receptor as a target, and introduces a certain amount of camel-derived natural phage display nanobody library for affinity screening. After four rounds of screening, soluble nanobodies that can specifically bind to the extracellular region of the sweet taste receptor are obtained. The nanobodies can be stably expressed and can elicit a response from sweet taste receptor cells, thus having a sweet taste effect. Attached Figure Description
[0034] Figure 1 This is a bar chart showing the phage-ELISA results of 48 clones randomly selected from the second, third, and fourth rounds of elution titer plates in the two screenings described in this embodiment of the invention. The red dashed line (S / N=2) represents the positive clone identification line. Among them, A: phage clones that target and bind to hT1R2-VFT in the fourth round; B: phage clones that target and bind to hT1R3-VFT in the third round.
[0035] Figure 2 This is a schematic diagram of SDS-PAGE of nanobody, lane M: low molecular weight protein marker, lanes 1-4: Nb T1R2-1 、Nb T1R2-14 、Nb N3-T1R3-2 、Nb N3-T1R3-30 .
[0036] Figure 3 The results of the indirect ELISA identification of nanobody functional activity described in the embodiments of the present invention are as follows: A: identification of activity targeting hT1R2-VFT protein; B: identification of activity targeting hT1R3-VFT protein.
[0037] Figure 4 The results of the inverted fluorescence microscope are from the calcium ion imaging experiment of the nanobody response to HEK293T cells described in this embodiment of the invention.
[0038] Figure 5 The image shows a fluorescence image of the nanobody described in this invention under an inverted fluorescence microscope, with a scale bar of 300 μm. Detailed Implementation
[0039] To facilitate understanding of the present invention, a more complete description will be provided below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a thorough and complete understanding of the disclosure of the present invention.
[0040] Unless otherwise specified, experimental methods in the following examples were performed under standard conditions, such as those described in the fourth edition of *Molecular Cloning: A Laboratory Manual*, edited by Green and Sambrook, published in 2013, or under conditions recommended by the manufacturer. All commonly used chemical reagents used in the examples are commercially available products.
[0041] Unless otherwise specified, experimental methods in the following examples are generally performed under standard conditions or as recommended by the manufacturer. All commonly used chemical reagents used in the examples are commercially available products.
[0042] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used in this specification is for the purpose of describing particular embodiments only and is not intended to limit the invention. The term "and / or" as used in this invention includes any and all combinations of one or more of the associated listed items.
[0043] The “antibody” in this article can be derived from any animal, including but not limited to humans and non-human animals. The non-human animals can be selected from primates, mammals, rodents and vertebrates, such as camels, llamas, ostriches, alpacas, sheep, rabbits, mice, rats or cartilaginous fish (e.g., sharks).
[0044] In this article, the letters in the amino acid sequence represent single-letter abbreviations of amino acids known in the art, such as those described in J. Biol. Chem, 243, p3558 (1968): Alanine: Ala-A, Arginine: Arg-R, Aspartic acid: Asp-D, Cysteine: Cys-C, Glutamine: Gln-Q, Glutamic acid: Glu-E, Histidine: His-H, Glycine: Gly-G, Asparagine: Asn-N, Tyrosine: Tyr-Y, Proline: Pro-P, Serine: Ser-S, Methionine: Met-M, Lysine: Lys-K, Valine: Val-V, Isoleucine: Ile-I, Phenylalanine: Phe-F, Leucine: Leu-L, Tryptophan: Trp-W, Threonine: Thr-T.
[0045] The terms “heavy chain variable region” and “VH” and “HCVR” used in this article are interchangeable, as are “light chain variable region” and “VL” and “LCVR”. The variable domains (VH and VL) of the heavy and light chains of natural antibodies generally have similar structures, with each domain containing four conserved frame regions (FRs) and three hypervariable regions (HVRs). See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p.91 (2007). A single VH or VL domain is sufficient to confer antigen binding specificity. The terms “complementarity-determining region” and “CDR” used in this article are interchangeable, and usually refer to the hypervariable region (HVR) of the heavy chain variable region (VH) or light chain variable region (VL). This region is called the complementarity-determining region because it can form precise complementarity with the antigen epitope in its spatial structure. The heavy chain variable region CDR can be abbreviated as HCDR, and the light chain variable region CDR can be abbreviated as LCDR.
[0046] The nanobodies in this invention can be mass-produced using genetic engineering techniques via recombinant expression. Specifically, the gene encoding the nanobodies is cloned into a suitable prokaryotic expression vector, and the nanobodies are prepared through protein expression. This invention employs prokaryotic expression as the protein expression method.
[0047] The nanobody described in this invention also relates to the functional activity identification in immunological detection and analysis, namely enzyme-linked immunosorbent assay (ELISA). In the early stage of functional activity identification, the nanobody is used in the form of protein for ELISA experiments; in the later stage of biological function identification, it is used in the form of protein for calcium ion imaging experiments to observe the intracellular calcium ion signal intensity.
[0048] This invention targets the extracellular region of sweet taste receptors and uses phage display technology to screen and enrich nanobodies that specifically bind to the extracellular region of sweet taste receptors. In vitro experiments verified the specific binding of the nanobodies to the sweet taste receptors, and cellular experiments verified that the nanobodies can increase intracellular calcium ion concentration. This invention provides, for the first time, nanobodies that can bind to sweet taste receptors and induce an increase in intracellular calcium ion concentration, suggesting that nanobodies may possess a sweet taste and hold promise as a novel sweetener, providing insights for the development of subsequent novel sweeteners or other food additives.
[0049] The present invention will be further described in detail below with reference to specific embodiments.
[0050] Example 1: Construction of a Camel-Derived Natural Phage Nanobody Display Library
[0051] The primers used for library construction are as follows:
[0052]
[0053] Note: Underlined sequences represent restriction endonuclease recognition sequences.
[0054] 1) Acute-derived cDNA samples: B lymphocytes were collected from the peripheral blood of 13 alpacas, and cDNA samples were obtained from 13 alpacas.
[0055] The samples were provided by Nanchang Dajia Biotechnology Co., Ltd.
[0056] 2) Nested PCR: The cDNA samples with sequence diversity collected from 13 alpacas were used as templates for the first round of PCR.
[0057] Amplification, the first round of PCR system is as follows:
[0058] reagents volume 5×PrimeSTARBuffer 10μL dNTPMixture (2.5μMeach) 4μL AlpVH-LD (10μM) 4μL CH2-R (10μM) 1μL PrimeSTAR (2.5U / μL) 0.5μL cDNA (10 ng / μL) 2.0μL <![CDATA[ddH2O]]> up to 50μL
[0059] PCR reaction conditions: 98℃ for 3 min; 98℃ for 5 s; 68℃ for 1 min; 72℃ for 5 min, for a total of 35 cycles.
[0060] 3) The DNA fragment recovery kit was used to recover the PCR products. After determining the concentration using Nanodrop 1000, the first-round PCR products were appropriately diluted and used as templates for the second-round PCR. The second-round PCR system is as follows:
[0061] reagents volume 5×PrimeSTARBuffer 10μL dNTPMixture (2.5μMeach) 4.0μL AlpVH-F3 (10μM) 1.0μL AlpVHHR1-NotⅠ or AlpVHHR2-NotⅠ (10 μM) 1.0μL PrimeSTAR (2.5U / μL) 0.5μL Template (10 ng / μL) 2.0μL <![CDATA[ddH2O]]> up to 50μL
[0062] PCR reaction conditions: 94℃ for 5 min; 94℃ for 30 s; 50℃ for 30 s; 72℃ for 1 min, for a total of 3 cycles; then 98℃ for 10 s; 68℃ for 1 min; 72℃ for 5 min, for a total of 30 cycles.
[0063] 4) Library Construction:
[0064] Double digestion of phage A with pHEN1 and PCR product
[0065] Phage particle pHEN1 and PCR products were digested with SfiI and NotI, respectively. SfiI digestion was performed at 50°C for 12–14 h, and complete digestion was confirmed by agarose gel electrophoresis. Then, NotI digestion was performed at 37°C for 6–8 h.
[0066] The cutting system is as follows:
[0067] reagents volume reagents volume 10×M Buffer 10μL 10×H Buffer 10μL pHEN1 or PCR product ~10μg 0.1% BSA 15μL SfiI 2.0μL 0.1% Triton X-100 15μL <![CDATA[ddH2O]]> up to 100μL The remaining system from the previous enzyme digestion step ~100μL NotI 2.0μL <![CDATA[ddH2O]]> up to 150μL
[0068] B connection
[0069] The phage vector and PCR product recovered after double enzyme digestion were ligated with T4 DNA ligase in a metal bath at 16℃ for 16 h. After ligation, the ligase was inactivated by incubation at 65℃ for 10 min.
[0070] C electroconversion
[0071] Add 3 μL (~750 ng) or 10 μL (~2500 ng) of the ligation product to 100 μL or 300 μL of Ecoli TG1 competent cells and incubate on ice for 30 min. Add the mixture to the bottom of a pre-chilled electroporation cuvette (1.8 kV) for electroporation. Add 1 mL of pre-warmed SOC medium to the cuvette to fully resuspend the bacterial culture, then aspirate the cuvette and rinse once with another 1 mL of pre-warmed SOC medium. Collect all the contents in a 50 mL Erlenmeyer flask and incubate at 37°C and 180 rpm for 1 h. Centrifuge at 4000 rpm for 10 min, then resuspend in 2×YT medium to a final volume of 25 mL. Take 10 μL to measure the volume of the culture, and spread the remainder evenly onto six 150 mm diameter 2×YT / A plates. Incubate at 30°C for 16 h.
[0072] D Library Collection
[0073] Scrape each large plate with 3 mL of 2×YT medium and collect the bacterial growth in 100 mL centrifuge tubes; after centrifugation and resuspending, add 25% glycerol to a final concentration, dispense 1 mL / tube, and store at -80℃.
[0074] 5) The rescue of the library
[0075] Seed cells at least 10 times their library volume in 100 mL of 2×YT / 2% glucose / Amp solution; incubate at 37°C and 220 rpm for 2–2.5 h until OD500. 600Approximately 0.5; add helper phage M13K07 at a multiplicity of infection ratio of 20:1, incubate at 37℃ for 15 min, then incubate at 220 rpm for 30–45 min; centrifuge at 3000g for 10 min, then resuspend the cells in fresh 2×YT / Amp / Kana, and incubate overnight at 30℃ and 250 rpm; centrifuge at 4℃ and 10000 rpm for 20 min to collect the phage supernatant, add 1 / 5 volume of PEG-NaCl solution, mix thoroughly, and incubate at 4℃ for >4 h; centrifuge at 4℃ and 10000 rpm for 20 min to completely remove the supernatant, resuspend the phage library in 1 mL of 1×PBS, take 10 μL to determine the library volume, add the remainder to a final concentration of 10–15% glycerol, and store at -80℃.
[0076] Example 2: Affinity screening and identification of nanobodies targeting the extracellular antigen protein of sweet taste receptors
[0077] 1) Affinity screening of nanobodies (two screenings were conducted).
[0078] Coating: The extracellular antigen protein of the sweet taste receptor designed in our laboratory (antigen protein sequence shown in Table 1) was diluted to 100 μg / mL with sterile 1×PBS (pH=7.4), and 100 μL / well was added to each well. Coating was carried out overnight at 4°C. Blocking:
[0079] Aspirate the coating solution, wash three times with PBS (incubate for 1 min each time), then add 300 μL / well of blocking buffer (3% BSA-PBS and 3% OVA-PBS alternately, block at 37°C for 2 h). For binding: aspirate the blocking buffer, wash three times with PBS (incubate for 1 min each time), then add 100 μL / well of the native phage nanobody display library (titer 2 × 10⁻⁶). 12 PFU / mL, and
[0080] The display library was incubated with an equal volume of blocking buffer at room temperature (20–30°C) for 1 hour. Washing: Aspirate the binding buffer, wash 5 times with 0.1% PBST (1 min each time), then wash 5 times with PBS (1 min each time). Elution:
[0081] Add 100 μL of Gly-HCl (pH = 2.2) to each well and incubate at 37°C for 6–8 min. Neutralization: Pipette the eluent from each well several times, then transfer the eluent to a clean 1.5 mL centrifuge tube. Add 90 μL of Tris-HCl to neutralize the eluent, mix thoroughly by pipetting, and use 10 μL to determine the titer. The remaining 180 μL will be used for amplification.
[0082] 2) Amplification and purification of eluted phages: 180 μL of the above eluent was inoculated into 5 mL of *E. coli* TG1 culture, incubated at 37°C for 6–8 min, and then incubated at 220 rpm for 30–45 min. Subsequently, it was added to 25 mL of fresh 2×YT / Amp medium and incubated at 37°C and 220 rpm until OD600 = 0.3–0.5. Based on the measured OD600 value, helper phage M13K07 was added at a ratio of 20:1 (multiple of infection), incubated at 37°C for 15 min, and then incubated at 220 rpm for 30–45 min. After centrifugation at 3000g for 10 min, the cells were resuspended in 25 mL of fresh 2×YT / Amp / Kana medium and incubated overnight at 30°C and 250 rpm on a shaker. The next day, the cells were centrifuged at 4°C and 7500 rpm for 15 min. The supernatant was collected, and 1 / 5 volume of PEG-NaCl was added. After thorough mixing, the cells were incubated at 4°C for at least 4 h to purify the phages. After phage purification, centrifuge at 7500 rpm for 30 min at 4℃, completely discard the supernatant, resuspend the phage library in 500 μL of 1×PBS, take 10 μL to determine the library volume, and store the remainder at 4℃ for the next round of screening.
[0083] 3) In the subsequent second, third, and fourth rounds of screening, the concentrations of the coated sweet taste receptor extracellular antigen were 50 μg / mL, respectively.
[0084] 25 μg / mL, 12.5 μg / mL. The number of washes with PBS and PBST increased by 3 times in each round, and the concentration of PBST increased by 0.1% in each round. The remaining steps were the same as above.
[0085] 4) Identification of positive clones: After two rounds of screening, 48 single colonies were randomly selected from the second, third and fourth rounds of elution titer plates. After phage rescue, positive phage clones were identified by indirect enzyme-linked immunosorbent assay (I-ELISA / phage-ELISA). The specific method for Phage-ELISA is as follows: Dilute the extracellular antigen protein of the sweet receptor to 5 μg / mL with PBS and coat overnight at 4℃; Blocking: Wash 3 times with 0.1% PBST, add 300 μL / well of 5% skim milk, and block at 37℃ for 2 h; Primary antibody binding: Discard the blocking solution, wash 6 times with 0.1% PBST, add 100 μL / well of phage supernatant (add according to the corresponding numbers), and incubate at 37℃ for 1 h; Secondary antibody binding: Discard the primary antibody, wash 8 times with 0.1% PBST, add 100 μL / well of HRP-labeled anti-M13 phage secondary antibody (1:7500 dilution), and incubate at 37℃ for 1 h; Color development: Discard the secondary antibody, wash 9 times with 0.1% PBST, add 100 μL / well of TMB colorimetric solution, and develop at 37℃ for 5-10 min; Termination: Add 50 μL / well of 2M H2SO4 to terminate the reaction; Reading:
[0086] Immediately after adding the stop solution, the OD was measured using a multi-function reader. 450 Value. When the experimental group OD 450 Value greater than negative control
[0087] OD 450 A value twice that of a positive clone is considered a positive clone.
[0088] Table 1. Extracellular region sequence of sweet taste receptors
[0089]
[0090]
[0091] Example 3: Determination of positive clone sequences and analysis of their amino acid sequences
[0092] Fresh LB / Amp was aliquoted into 1.5 mL centrifuge tubes at 900 μL / tube. Single colonies of the positive clones were picked and incubated in 1.5 mL centrifuge tubes containing fresh LB / Amp at 37°C and 220 rpm for 6–7 h (until the culture was turbid). The cultures were then sent to Shanghai Sangon Biotech Co., Ltd. for Sanger sequencing. After sequencing, the target sequence was extracted using SeqMan software and translated into a protein sequence using MegAlin software. Multiple sequence alignment analysis was performed to obtain the partial amino acid sequence encoding the complete nanobody and its framework and variable regions, as shown in Table 2.
[0093] Table 2
[0094]
[0095]
[0096]
[0097] Example 4: Large-scale preparation of positive nanobodies encoding complete amino acid sequences in protein expression form.
[0098] Plasmid extraction: Straw the correctly sequenced positive clones onto LB / Amp plates and incubate them upside down at 37°C for 12–16 h; pick a single colony and incubate it in 5 mL of LB / Amp liquid medium at 37°C and 220 rpm for 12 h; extract the phage plasmid pHEN1-Nbs according to the instructions of the plasmid extraction kit.
[0099] Seamless cloning: PCR amplification was performed on the pET25b vector and the phage particle pHEN1-Nbs to obtain a linearized vector and the target fragment. The PCR products were recovered using a gel extraction kit, and the product concentration was determined using Nanodrop 1000. The product band size was verified by agarose gel electrophoresis. The target fragment was then cloned into the pET25b vector using the Mona Seamless Cloning Kit. The ligation product was electroporated into E. coli DH5α. 100 μL of the incubated bacterial solution was evenly spread on LB / Amp plates and incubated upside down at 37°C for 12 h. On the second day, colony PCR was performed on randomly selected clones from the transformation plates. Positive clones were selected, and the bacterial solution was cultured until turbid before being sent to Shanghai Sangon Biotech Co., Ltd. for Sanger sequencing.
[0100] Nanobody expression: The plasmid was cloned according to the Tiangen micro-extract plasmid. After appropriate dilution, the plasmid was transferred to *E. coli* BL21(DE3) and plated on LB / Amp plates, incubated upside down at 37°C for 12 h. A single colony was picked from the transformed plate and inoculated into a 5 mL LB / Amp tube, incubated overnight at 37°C and 220 rpm. The next day, the overnight culture was transferred to 50 mL LB / Amp medium at a 1% inoculum and incubated at 37°C and 220 rpm until OD500. 600 When the concentration of the protein was 0.6, 0.1 mM IPTG was added, and the mixture was incubated overnight at 16°C and 180 rpm. The culture was centrifuged at 4°C and 6500 rpm for 15 min, and the bacterial pellet was collected. The pellet was resuspended in 1 / 10 volume of pre-chilled LE Buffer, and then lysed on ice for 4 min. The lysed culture was centrifuged at 4°C and 10000 rpm for 10 min, and the supernatant was collected. After filtration through a 0.45 μm filter, the culture was purified by affinity chromatography using a nickel column to obtain the expressed nanobody. The protein concentration was determined using the Beyotime Brandford Protein Assay Kit.
[0101] Results and Analysis:
[0102] After two rounds of solid-phase screening of the phage library, 48 clones were randomly selected from the elution titer plates of the second, third, and fourth rounds, respectively, for a total of 96 clones. These clones were then subjected to phage-ELISA assays for identification (the cloning naming principle of this invention is: clones 1-48 are named according to antigen name-order, and clones 49-96 are named according to screening round-antigen name-order). Figure 1 As shown. The red dashed line (S / N=2) represents the positive clone identification line. After ELISA identification, Sanger sequencing, and multiple sequence alignment analysis, four clones with unique sequences were selected, corresponding to... Figure 1 Clones 1, 14, 50, and 78 of Nb T1R2-1 、Nb T1R2-14 、Nb N3-T1R3-2 、Nb N3-T1R3-30 Protein expression was performed for subsequent identification.
[0103] SDS-PAGE electrophoresis image of nanobodies bound to the extracellular region of sweet taste receptors after purification by nickel column resin gel affinity chromatography, as shown. Figure 2 As shown, lane M is a low molecular weight marker, and the other lanes are the target proteins eluted by 250mM imidazole from four nanobodies.
[0104] The SDS-PAGE electrophoresis results show that all four nanobodies have bands at around 20 kDa, indicating that soluble nanobodies can be expressed by low-temperature overnight induction at 16°C, 180 rpm, and 0.1 mM IPTG.
[0105] Example 5 Indirect ELISA Experiment
[0106] This invention provides an indirect ELISA method to verify the binding activity of nanobodies to the extracellular region of an antigen sweetness receptor, comprising the following steps:
[0107] Coating: Dilute the antigen (extracellular region of sweet taste receptor) protein to 50 μg / mL with sterile 1×PBS, add 100 μL / well to the wells of the ELISA plate, and coat overnight at 4°C.
[0108] Blocking: Wash 3 times with 0.05% PBST, add 300 μL / well of 5% skim milk blocking solution, and block at 37°C for 2 h.
[0109] Primary antibody: Wash 3 times with 0.05% PBST, dilute the nanobody to 50 μg / mL with sterile 1×PBS, add 100 μL / well to the well of the ELISA plate, and bind at 37℃ for 1 h.
[0110] Secondary antibody: Wash 6 times with 0.05% PBST, add 100 μL / well of HRP / Anti-CamelidVHH secondary antibody (1:5000 dilution) and bind at 37℃ for 1 h.
[0111] Color development: Wash 6 times with 0.05% PBST, add 100 μL / well of TMB color development solution, and develop at 37℃ for 10 min.
[0112] Termination: Stop color development with 50 μL / well 2M H2SO4, and immediately measure OD under a multi-function reader. 450 value.
[0113] Data analysis: Graphpad software was used to create bar charts, and Two-way ANOVA was used to analyze differences between groups.
[0114] Experimental results showed that in the indirect ELISA experiment, all four nanobodies described in this invention exhibited significant differences compared to the control group. Specifically, in the identification of the activity of the nanobodies targeting and binding to hT1R2-VFT, Nb... T1R2-1 、Nb T1R2-14 Significant differences were observed between the Nb group and the hT1R3-VFT coated group, the negative control group, and the blank control group, indicating that Nb... T1R2-1 、Nb T1R2-14 It specifically binds to hT1R2-VFT, and OD 450 The value is around 1.0, indicating a relatively high signal strength. Nb N2-T1R2-42 Although there were significant differences compared to the negative and blank control groups, there were no significant differences compared to the hT1R3-VFT coated group, indicating that Nb N2-T1R2-42 It exhibits cross-reactivity with hT1R3-VFT, and OD 450 Value below Nb T1R2-1 and Nb T1R2-14 Nb N2-T1R2-48 No activity was indicated by no significant difference compared to the negative control and blank control. In the activity identification of nanobodies targeting and binding to hT1R3-VFT, Nb... N3-T1R3-2 、Nb N3-T1R3-30 Significant differences were observed between the Nb group and the hT1R2-VFT coated group, the negative control group, and the blank control group, indicating that Nb... N3-T1R3-2 、Nb N3-T1R3-30 It specifically binds to hT1R3-VFT, in which Nb N3-T1R3-2 OD 450 The value is around 1.8, the signal strength is very strong, Nb N3-T1R3-30 OD 450 The signal value is around 1.0, indicating a high signal strength. Other activity assays of nanobodies bound to hT1R3-VFT show that Nb... N4-T1R3-16It showed cross-reactivity with hT1R2-VFT and no significant difference from the negative and blank control groups, indicating that Nb N4-T1R3-16 Inactive, Nb N2-T1R3-48 Although there was a significant difference compared to the hT1R2-VFT coated group, suggesting specific binding to hT1R3-VFT, OD 450 The value is lower compared to the other two nanobodies. Of the four nanobodies in this invention that specifically bind to the extracellular region of the sweetness receptor, Nb... N3-T1R3-2 The signal value is the highest, such as Figure 3 As shown.
[0115] Example 6: Calcium Ion Imaging
[0116] Cell culture: HEK293T cells were cultured in complete medium (10% FBS + DMEM) at 37℃ and 5% CO2. After the cells were stabilized by 2-3 passages, they were transfected at 10⁻⁶ cells / mL for 12-24 hours before transfection. 6 One cell per well is seeded into a six-well cell culture plate.
[0117] Plasmid transfection: Before transfection, replace the cell culture medium with fresh complete culture medium, following the instructions from Beyotime Lipo8000.
[0118] Prepare the transfection complex according to the transfection reagent instructions (each well of a 6-well plate contains 125 μL antibiotic-free DMEM + 2.5 μg DNA + 4 μL Lipo8000). Add the full-length sweet taste receptor (see reference Park J, Selvam B, Sanematsu K, et al. Structural architecture of a dimeric class C GPCR based on co-trafficking of sweet taste receptor subunits[J]. Journal of Biological Chemistry,
[0119] 2019, 294(13):4759-4774) and G protein (see reference Zanini S, Giovinazzo F, Alaimo D, et al. GNA15 expression in small intestinal neuroendocrine neoplasia: Functional and signalling pathway analyses[J]. Cellular Signalling, 2015, 27(5):899-907.) were co-transfected into HEK293T cells (the ratio of the three proteins was 1:1:1). After culturing the cells for 4-6 hours, the culture medium was replaced with fresh complete culture medium and cultured for another 24-48 hours.
[0120] Calcium ion imaging: Wash cells 2-3 times with sterile PBS to remove serum and other components from the culture medium. Prepare Flou-4 staining solution according to the Beyotime Fluo-4 calcium ion detection kit, add 1 mL / well to a 6-well cell culture plate, incubate at 37°C in the dark for 30 min, then wash 2-3 times with PBS. Add 500 μL / well of test buffer and continue incubation at 37°C in the dark for 15-20 min. Add 500 μL / well of 2× test solution (positive control: 300 mM sucrose and 25 mM cyclamate; blank control: 40 mM imidazole; negative control: nanobody that does not bind to sweet taste receptors; experimental group: nanobody to be tested, the concentration of nanobody detected in the experiment is 1 μM), incubate at 37°C for 5 min, then excite under an inverted fluorescent lamp in the green fluorescence channel to observe fluorescence, take pictures to record fluorescence images, and analyze the fluorescence values of the images using ImageJ.
[0121] Experimental results showed that in the calcium ion imaging experiment, Nb in the experimental group T1R2-1 and Nb T1R2-14 The fluorescence value was higher than that of the negative control and the blank control, indicating that Nb T1R2-1 and Nb T1R2-14 After binding to sweet taste receptors, it can cause an increase in intracellular calcium ion concentration. Compared with the positive control sucrose, Nb T1R2-1 and Nb T1R2-14 The fluorescence value of Nb was significantly enhanced. N2-T1R2-42 Although the fluorescence value of Nb was higher than that of the negative and blank controls, and slightly higher than that of sucrose, its fluorescence intensity was significantly weaker than that of Nb. T1R2-1 and Nb T1R2-14 In nanobodies that specifically bind to T1R2, Nb T1R2-14 It exhibits high fluorescence values. Nb N3-T1R3-2 and Nb N3-T1R3-30 The fluorescence values of these nanobodies were higher than those of the negative control and the blank control group, indicating that these two nanobodies can bind to sweet taste receptors and cause an increase in intracellular calcium ion concentration, and NbN3-T1R3-2 The fluorescence value was significantly higher than that of cyclamate, Nb N3-T1R3-30 Its fluorescence value is comparable to that of cyclamate, while Nb... N2-T1R3-48 The fluorescence value of [the substance] is lower than that of [the substance], and is related to Nb. N3-T1R3-2 and Nb N3-T1R3-30 Compared to the previous year, the fluorescence value was lower, indicating that Nb N3-T1R3-2 and Nb N3-T1R3-30 This leads to a greater increase in intracellular concentration, suggesting stronger functional activity through binding to sweet taste receptors. All four nanobodies described in this invention can stimulate the response of sweet taste receptors to varying degrees, i.e., an increase in intracellular calcium ion concentration. Among the four nanobodies, Nb... T1R2-14 The fluorescence value of Nb is the strongest. N3-T1R3-2 Secondly, such as Figure 4 and Figure 5 As shown.
[0122] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.
Claims
1. A nanobody for a sweetener comprising a framework region and complementarity determining regions, characterized in that, The nanobody is selected from at least one of the following: a. The frame regions are shown in SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13 and SEQ ID NO:15, and the complementary determination regions CDR1 to CDR3 are shown in SEQ ID NO:10, SEQ ID NO:12 and SEQ ID NO:14; b. The frame regions are shown in SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21 and SEQ ID NO:23, and the complementary determination regions CDR1 to CDR3 are shown in SEQ ID NO:18, SEQ ID NO:20 and SEQ ID NO:22; c. The frame regions are shown in SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29 and SEQ ID NO:31, and the complementarity determination regions CDR1 to CDR3 are shown in SEQ ID NO:26, SEQ ID NO:28 and SEQ ID NO:30; d. The frame regions are shown in SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 and SEQ ID NO:39, and the complementarity determination regions CDR1 to CDR3 are shown in SEQ ID NO:34, SEQ ID NO:36 and SEQ ID NO:
38.
2. The Nanobody for a sweetener according to claim 1, characterized in that, The amino acid sequence of the nanobody is as shown in any one of SEQ ID NO:1-SEQ ID NO:4, or the nanobody is selected from the amino acid sequences shown in SEQ ID NO:1-SEQ ID NO:4 by substitution, deletion or addition of one or more amino acids without changing its sweetener activity.
3. The Nanobody for a sweetener according to claim 2, characterized in that, The amino acid sequence of the nanobody is shown in SEQ ID NO:
2.
4. A nucleic acid molecule encoding a nanobody for a sweetener as described in any one of claims 1-3.
5. The nucleic acid molecule of claim 4, wherein As shown in SEQ ID NO:5-SEQ ID NO:
8.
6. A vector containing the nucleic acid molecule of claim 4 and capable of expressing the nanobody, preferably, the vector is a plasmid, a bacteriophage, a granule, a bacteriophage or viral vector, preferably a prokaryotic vector pET25b plasmid.
7. A host cell characterized by, The host cell expresses the nanobody according to any one of claims 1-3; Preferably, the host cell is a prokaryotic cell, and more preferably, Escherichia coli BL21(DE3); More preferably, the host cell is a bacterial cell or a yeast cell.
8. A method for preparing nanobodies for sweeteners according to any one of claims 1-3, characterized in that, Includes the following steps: Culture the host cells according to claim 7 to obtain the nanobody from the culture; or The results were obtained through phage display technology using sweet taste receptor extracellular antigen proteins; Preferably, The nucleic acid molecule encoding the nanobody of any one of claims 1-3 is cloned into a prokaryotic expression vector, cultured, and the polypeptide is extracted from the culture, purified, and the nanobody is obtained. Preferably, the sweet taste receptor extracellular antigen protein is as shown in SEQ ID NO:41 and / or SEQ ID NO:
42.
9. The use of the nanobody according to any one of claims 1-3, or the carrier according to claim 6, or the host cell according to claim 7 in the preparation of sweeteners.
10. A sweetener, the main active ingredient of which includes the nanobody according to any one of claims 1-3, the carrier according to claim 6, or the host cell according to claim 7.
